Chief Medical Officer
Dr. Doug Wilson joined FPG in 2010 to augment our capabilities in analyzing the existing and planned drugs and devices from both established and young Pharma/Biotech companies and their Medtech counterparts. Doug uses his extensive experience at Boehringer Ingelheim to cover Clinical Development and R&D review assessment in his work for FPG and its clients, making him an invaluable part of our due diligence process. Doug’s expertise forms an integral part of the Ferghana process of advising clients.
Doug’s had ten years of experience at Boehringer Ingelheim as Head of Medical and Regulatory Affairs in the US where he oversaw a team of over 400 including a number of medical staff, and then worldwide in Germany. Doug also had responsibility for over 60 parallel drug developments (including all clinical studies, data management and statistics and all interactions with academics, investigators and the FDA). Doug’s post-graduate experience was as Researcher at numerous prestigious institutions including the St Thomas Hospital Medical School, London and the Imperial Cancer Research Fund. Doug worked at Auckland Medical School as Associate Professor in the Department of Medicine and as Head of Department of Immunology at Auckland Hospital.
Dr Wilson has published over 100 papers in refereed journals and is author or editor of four text books.